Vir Biotechnology

Yahoo Finance • last year

Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference

SAN FRANCISCO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Vir’s Executive Vice President, Chief Medical Officer and Interim Head of Research, is participating in a... Full story

Yahoo Finance • last year

Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023

SAN FRANCISCO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that eight abstracts highlighting new data from its chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) clinical programs have... Full story

Yahoo Finance • last year

Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023

SAN FRANCISCO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2023, on November 2... Full story

Yahoo Finance • last year

Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats

– New investment of approximately $50 million from Biomedical Advanced Research and Development Authorityincludes $40 million in Project NextGen funds – – Contract expands existing support for the development of candidates for prevention... Full story

Yahoo Finance • last year

Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV

– Based on a novel human cytomegalovirus vector platform, VIR-1388 was designed with the goal of creating a novel HIV vaccine – – Phase 1 trial supported by the Bill & Melinda Gates Foundation, the National Institute of Allergy and Infect... Full story

Yahoo Finance • last year

Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences

SAN FRANCISCO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that management will be participating in the following upcoming investor conferences during the month of September: Morgan Stanley 21... Full story

Yahoo Finance • last year

11 Most Profitable Biotech Stocks Today

In this piece, we will take a look at the 11 most profitable biotechnology stocks to buy today. If you want to skip our introduction to the biotechnology industry and want to take a look at the top five stocks in this list, then head on ov... Full story

Yahoo Finance • last year

Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer

SAN FRANCISCO, June 29, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer, effective July 10, 2023. Ms. D... Full story

Yahoo Finance • last year

Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL™ Congress 2023

Late-breaking data from BRII-835 + PEG-IFN-a study demonstrate anti-HBs titers at the end of treatment were associated with sustained HBsAg loss 24 weeks after the end of treatment New data show more robust and persistent anti-HBs titers... Full story

Yahoo Finance • last year

Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D

– Data from two ongoing clinical trials in people living with chronic hepatitis B infection suggest the combination of an antiviral with an immunomodulator can achieve rapid and deep declines in hepatitis B virus surface antigen (HBsAg) an... Full story

Yahoo Finance • last year

Vir Biotechnology to Host a Virtual-Only 2023 Annual Meeting of Stockholders

SAN FRANCISCO, May 17, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2023 Annual General Meeting of Stockholders on Friday, May 19, 2023, at 11:30 a.m. PT. The Annual Meet... Full story

Yahoo Finance • last year

Vir Biotechnology, Inc. (NASDAQ:VIR) is favoured by institutional owners who hold 50% of the company

Key Insights Institutions' substantial holdings in Vir Biotechnology implies that they have significant influence over the company's share price A total of 6 investors have a majority stake in the company with 52% ownership Recent sales b... Full story

Yahoo Finance • last year

Vir Biotechnology Appoints Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer

SAN FRANCISCO, May 15, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer. Dr. Calcagno will be responsible for le... Full story

Yahoo Finance • 2 years ago

Vir Biotechnology to Participate in the 22nd Annual Needham Virtual Healthcare Conference

SAN FRANCISCO, April 11, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Executive Vice President, Chief Medical Officer and Interim Head of Research, is scheduled to participat... Full story

Yahoo Finance • 2 years ago

Vir Biotechnology to Participate in the Barclays Global Healthcare Conference

SAN FRANCISCO, March 08, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Executive Vice President, Chief Medical Officer and Interim Head of Research, is scheduled to present at... Full story

Yahoo Finance • 2 years ago

As Covid Threat Weakens, This Biotech Is Still Worth a Shot

Vir Biotechnology, Inc. is a biotech company facing the apparent winding down of the Covid crisis while sitting on a huge amount of net cash -- and with other projects in the pipeline. Vir uses this information to develop way of treating i... Full story

Yahoo Finance • 2 years ago

Vir Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference

SAN FRANCISCO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Bolyn Hubby, Ph.D., Executive Vice President and Chief Corporate Affairs Officer, will participate in a panel focused on infectio... Full story

Yahoo Finance • 2 years ago

Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK’s National Institute for Health and Care Excellence (NICE)

SAN FRANCISCO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the UK’s National Institute for Health and Care Excellence (NICE) provided positive final draft guidance recommending the use of... Full story

Yahoo Finance • 2 years ago

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023

SAN FRANCISCO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2022,... Full story

Yahoo Finance • 2 years ago

Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor

– Dr. De Backer to assume CEO role on April 3, 2023 – – Upon his retirement as CEO,Dr.Scangos will transition to an advisory role through June 2, 2023 and will continue providing strategic counsel to Vir as a member of the Board of Direct... Full story